Sun Pharmaceutical had sought grant of 'emergency authorisation status' to its plant-based drug, ACQH, which is being developed as a potential treatment for dengue.
Sun Pharma said human safety study of AQCH already completed, clinical trials will be conducted across 12 centres on 210 patients. The treatment duration will be 10 days.
The Mumbai-based drug-maker has submitted a proposal to the govt to conduct Phase II clinical trials of the drug to see if it can treat patients suffering from Covid-19.
The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
By the 2024 US Open, ESPN noted that Djokovic had advanced via opponent retirements or walkovers 16 times at Majors, the most of any male player in the Open Era.
In AICC report ‘Real State of the Economy 2026’, Congress flags ‘central contradiction’ in economy, calls for data review pointing to jobs, FDI, manufacturing slump & inequality.
Shield AI will provide V-BAT vertical takeoff & landing drones along with licences for software, which will be integrated into aircraft and made available to select Indian partners.
No nation other than China can negotiate one-on-one with Trump on an equal footing. That’s why the middle powers who so far formed the core of multilateral bodies now feel orphaned.
COMMENTS